CAPTRUST Financial Advisors
CTKB icon

CAPTRUST Financial Advisors’s Cytek Biosciences CTKB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.9K Sell
13,068
-3,366
-20% -$14.4K ﹤0.01% 3120
2026
Q1 		$71.8K Buy
16,434
+2,387
+17% +$11.3K ﹤0.01% 2855
2025
Q4 		$70.9K Sell
14,047
-1,231
-8% -$5.72K ﹤0.01% 2645
2025
Q3 		$53K Buy
15,278
+2,574
+20% +$9.66K ﹤0.01% 2557
2025
Q2 		$43.2K Buy
+12,704
New +$42.3K ﹤0.01% 2439
2022
Q3 		– Sell
-338
Closed -$4K – 2495
2022
Q2 		$4K Sell
338
-26
-7% -$259 ﹤0.01% 4172
2022
Q1 		$4K Buy
+364
New +$4.92K ﹤0.01% 4238

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAPTRUST Financial Advisors's CTKB Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its Cytek Biosciences (CTKB) stake by 20% in Q2 2026, selling an estimated $14.4K and leaving 13,068 shares worth $57.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3120.

CAPTRUST Financial Advisors first reported a position in CTKB in Q1 2022 and has held it in 7 quarters since. The position peaked at $71.8K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • CAPTRUST Financial Advisors held 13,068 shares of Cytek Biosciences worth $57.9K as of Q2 2026.
  • CAPTRUST Financial Advisors sold 3,366 Cytek Biosciences shares in Q2 2026, an estimated $14.4K.
  • Cytek Biosciences made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3120 holding.
  • CAPTRUST Financial Advisors first reported a position in Cytek Biosciences in Q1 2022 and has held it in 7 quarters since.
  • CAPTRUST Financial Advisors's Cytek Biosciences position peaked at $71.8K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.